{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:27:38Z","timestamp":1793291258451,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Haiyan Fund of Harbin Medical University Cancer Hospital","award":["JJMS-2023-05"],"award-info":[{"award-number":["JJMS-2023-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11604-025-01920-4","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:57:23Z","timestamp":1767585443000},"page":"383-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["18F-PSMA-1007 PET\/CT tumor volume quantification: a game-changing prognostic biomarker for first-line ARPI therapy in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Liping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1920_CR1","doi-asserted-by":"publisher","first-page":"107932","DOI":"10.1016\/j.pharmthera.2021.107932","volume":"228","author":"M Adamaki","year":"2021","unstructured":"Adamaki M, Zoumpourlis V. Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 2021;228:107932. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107932.","journal-title":"Pharmacol Ther"},{"key":"1920_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473\u201380. https:\/\/doi.org\/10.15585\/mmwr.mm6941a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1920_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13685538.2022.2053954","volume":"25","author":"A Alwhaibi","year":"2022","unstructured":"Alwhaibi A, Alsanea S, Almadi B, Al-Sabhan J, Alosaimi FD. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management. Aging Male. 2022;25:101\u201324. https:\/\/doi.org\/10.1080\/13685538.2022.2053954.","journal-title":"Aging Male"},{"key":"1920_CR4","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129:4492\u2013505. https:\/\/doi.org\/10.1172\/JCI128212.","journal-title":"J Clin Invest"},{"issue":"2","key":"1920_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"13","key":"1920_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"issue":"5","key":"1920_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"issue":"5","key":"1920_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"WP Fendler","year":"2021","unstructured":"Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Eur Urol. 2021;79(5):648\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013.","journal-title":"Eur Urol"},{"issue":"20","key":"1920_CR9","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1200\/JCO.21.02612","volume":"40","author":"MJ Morris","year":"2022","unstructured":"Morris MJ, Rowe SP, Gorin MA. Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR study. J Clin Oncol. 2022;40(20):2302\u201312. https:\/\/doi.org\/10.1200\/JCO.21.02612.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1920_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer. J Urol. 2021;206(1):52\u201361. https:\/\/doi.org\/10.1097\/JU.0000000000001698.","journal-title":"J Urol"},{"issue":"1","key":"1920_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.119.240440","volume":"62","author":"M Eiber","year":"2021","unstructured":"Eiber M, Herrmann K, Calais J. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2021;62(1):85\u201393. https:\/\/doi.org\/10.2967\/jnumed.119.240440.","journal-title":"J Nucl Med"},{"issue":"5","key":"1920_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2967\/jnumed.122.264887","volume":"64","author":"MS Hofman","year":"2023","unstructured":"Hofman MS, Emmett L, Sandhu S. PSMA-PET\/CT-guided intensification of androgen receptor pathway inhibition in metastatic prostate cancer: results from the phase II ENZA-PET trial. J Nucl Med. 2023;64(5):715\u201321. https:\/\/doi.org\/10.2967\/jnumed.122.264887.","journal-title":"J Nucl Med"},{"issue":"5","key":"1920_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3145","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Weber M, Iravani A. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28(5):928\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3145.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1920_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.120.254623","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. Whole-body PSMA PET\/CT tumor volume as a quantitative biomarker for risk stratification in metastatic castration-resistant prostate cancer. J Nucl Med. 2021;62(7):947\u201354. https:\/\/doi.org\/10.2967\/jnumed.120.254623.","journal-title":"J Nucl Med"},{"issue":"12","key":"1920_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S1470-2045(22)00646-3","volume":"23","author":"MS Hofman","year":"2022","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. PRIMARY trial: prospective validation of PSMA-PET\/CT for initial staging in prostate cancer\u2014impact on treatment decisions and prognostic value. Lancet Oncol. 2022;23(12):1511\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(22)00646-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1920_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euo.2022.11.006","volume":"6","author":"SP Rowe","year":"2023","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Comparative analysis of 68Ga- and 18F-labeled PSMA-targeted tracers in prostate cancer imaging: a systematic review. Eur Urol Oncol. 2023;6(2):180\u20139. https:\/\/doi.org\/10.1016\/j.euo.2022.11.006.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"1920_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1920_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.radonc.2019.07.002","volume":"141","author":"C Zamboglou","year":"2019","unstructured":"Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M. Validation of different PSMA-PET\/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol. 2019;141:208\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.002.","journal-title":"Radiother Oncol"},{"key":"1920_CR19","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.5001\/omj.2021.117","volume":"37","author":"S Kumar","year":"2022","unstructured":"Kumar S, Burney IA, Kunju J, Al-Marhoon MS, Siddiqui KM. Clinicopathological features, treatment, and outcome of Omani patients with metastatic prostate cancer. Oman Med J. 2022;37:e333. https:\/\/doi.org\/10.5001\/omj.2021.117.","journal-title":"Oman Med J"},{"key":"1920_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2967\/jnumed.120.256602","volume":"62","author":"AG Wibmer","year":"2021","unstructured":"Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson S. Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: a single-center retrospective cohort study. J Nucl Med. 2021;62:1050\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.256602.","journal-title":"J Nucl Med"},{"key":"1920_CR21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41391-021-00391-8","volume":"24","author":"M Bauckneht","year":"2021","unstructured":"Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V. The prognostic power of 18F-FDG PET\/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021;24:1198\u2013207. https:\/\/doi.org\/10.1038\/s41391-021-00391-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"1920_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s002590100508","volume":"28","author":"SM Okarvi","year":"2001","unstructured":"Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28(7):929\u201338. https:\/\/doi.org\/10.1007\/s002590100508.","journal-title":"Eur J Nucl Med"},{"key":"1920_CR23","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1097\/RLU.0000000000001589","volume":"42","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT. Multiple time-point 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42:e286\u201393. https:\/\/doi.org\/10.1097\/RLU.0000000000001589.","journal-title":"Clin Nucl Med"},{"key":"1920_CR24","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","volume":"45","author":"Q Zou","year":"2020","unstructured":"Zou Q, Jiao J, Zou MH, Li MZ, Yang T, Xu L. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of (68) Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer. Abdom Radiol (NY). 2020;45:4202\u201313. https:\/\/doi.org\/10.1007\/s00261-020-02745-7.","journal-title":"Abdom Radiol (NY)"},{"key":"1920_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12149-019-01342-z","volume":"33","author":"AET Brito","year":"2019","unstructured":"Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL. Evaluation of whole-body tumor burden with (68) Ga-PSMA PET\/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019;33:344\u201350. https:\/\/doi.org\/10.1007\/s12149-019-01342-z.","journal-title":"Ann Nucl Med"},{"key":"1920_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MNM.0000000000001522","volume":"43","author":"DR Cardoza-Ochoa","year":"2022","unstructured":"Cardoza-Ochoa DR, Cristancho-Rojas C, Perez DJ, Moreno-Izaguirre P, Guzman M, Gutierrez-Rivera MC. Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer. Nucl Med Commun. 2022;43:332\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001522.","journal-title":"Nucl Med Commun"},{"key":"1920_CR27","doi-asserted-by":"publisher","first-page":"20190380","DOI":"10.1259\/bjr.20190380","volume":"92","author":"S Suman","year":"2019","unstructured":"Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S. Therapeutic efficacy, prognostic variables and clinical outcome of (177) Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort. Br J Radiol. 2019;92:20190380. https:\/\/doi.org\/10.1259\/bjr.20190380.","journal-title":"Br J Radiol"},{"key":"1920_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12149-022-01785-x","volume":"36","author":"TA Telli","year":"2022","unstructured":"Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N. Role of baseline (68) Ga-PSMA PET\/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022;36:964\u201375. https:\/\/doi.org\/10.1007\/s12149-022-01785-x.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1920_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1967\/s002449910952","volume":"22","author":"NK Pianou","year":"2019","unstructured":"Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET\/CT. Hell J Nucl Med. 2019;22(1):6\u20139. https:\/\/doi.org\/10.1967\/s002449910952.","journal-title":"Hell J Nucl Med"},{"key":"1920_CR30","doi-asserted-by":"publisher","first-page":"3502389","DOI":"10.1155\/2021\/3502389","volume":"2021","author":"M Ferrari","year":"2021","unstructured":"Ferrari M, Treglia G. 18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis. Contrast Media Mol Imaging. 2021;2021:3502389. https:\/\/doi.org\/10.1155\/2021\/3502389.","journal-title":"Contrast Media Mol Imaging"},{"issue":"12","key":"1920_CR31","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3390\/diagnostics12123176","volume":"12","author":"L Saule","year":"2022","unstructured":"Saule L, Radzina M, Liepa M, Roznere L, Lioznovs A, Ratniece M. Recurrent prostate cancer diagnostics with 18F-PSMA-1007 PET\/CT: a systematic review of the current state. Diagnostics. 2022;12(12):3176. https:\/\/doi.org\/10.3390\/diagnostics12123176.","journal-title":"Diagnostics"},{"issue":"3","key":"1920_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MOU.0000000000000982","volume":"32","author":"R Mei","year":"2022","unstructured":"Mei R, Farolfi A, Morigi JJ, Fanti S. The role of prostate-specific membrane antigen PET\/computed tomography in the management of prostate cancer patients: Could we ask for more? Curr Opin Urol. 2022;32(3):269\u201376. https:\/\/doi.org\/10.1097\/MOU.0000000000000982.","journal-title":"Curr Opin Urol"},{"issue":"5","key":"1920_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","volume":"46","author":"A Heinzel","year":"2019","unstructured":"Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D. 68Ga-PSMA PET\/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1054\u201362. https:\/\/doi.org\/10.1007\/s00259-019-4258-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1920_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62(5):596\u2013604. https:\/\/doi.org\/10.2967\/jnumed.120.257238.","journal-title":"J Nucl Med"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01920-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:36:15Z","timestamp":1769841375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01920-4","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"\u2018The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Institutional Review Board and Ethical Committee of Harbin Medical University Cancer Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}